Recently, bioGenous officially obtained the "Experimental Animal Use Permit" (License Number: SYXK(Lu) 2023 0039) issued by the Department of Science & Technology of Shandong Province and the Shandong Provincial Experimental Animal Management Committee. This signifies that the bioGenous Experimental Animal Center now possesses the qualifications and conditions to engage in the breeding of experimental animals and the establishment of PDOX models for drug research and development.
The experts of the Department of Science & Technology of Shandong Province conducted on-site acceptance and guidance of bioGenous Experimental Animal Center by listening to reports, reviewing materials, and examing questions. After examination, bioGenous Experimental Animal Center successfully obtained the "Experimental Animal Use Permit".
The experts conducted acceptance and guidance in the animal room
The experts listened to the application report and reviewed the application materials
The bioGenous Experimental Animal Center is located in the National North Emergency(Medical) Rescue Comprehensive Demonstration Zone, Tianqu New District, Dezhou, Shandong Province. With a total construction area of 2,000 square meters, it boasts 1,000 square meters of SPF-grade experimental animal facilities capable of accommodating standardized and large-scale breeding of over one thousand cages of mice. Leveraging this platform, bioGenous will further enhance its whole-process service capabilities in organoid modeling and accelerate the application of organoid technology in the pharmaceutical industry.
bioGenous has deeply engaged in bottom-up technological innovation within the organoid industry. The company's scientific team has utilized human-derived organoids and xenotransplantation technology to establish various models, including embryonic thyroid development models and tumorigenesis and metastasis models for multiple types of neuroblastomas. The commissioning of the Experimental Animal Center will provide strong support for Bozhen Biology to continuously develop innovative organoid modeling platforms and applications, offering new drug discovery and pharmacodynamics evaluation services based on PDOX (Patient-Derived Organoid Xenograft) models to pharmaceutical research and development enterprises.
Overview of Animal Room
Individual Ventilated Cages
In the next phase of work, bioGenous will adhere to strict management in accordance with national standards, providing more comprehensive model platforms and solid technical service support for the conduct of life science and medical research.
